BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 37818930)

  • 1. A cost-effectiveness analysis of national smoking cessation services among chronic obstructive pulmonary disease patients in Thailand.
    Prasitwarachot R; Thavorn K; Patikorn C; Wattanasirichaigoon S; Rungruanghiranya S; Thongphiew A; Chaiyakunapruk N
    J Med Econ; 2023; 26(1):1377-1385. PubMed ID: 37818930
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Simulation-based estimates of effectiveness and cost-effectiveness of smoking cessation in patients with chronic obstructive pulmonary disease.
    Atsou K; Chouaid C; Hejblum G
    PLoS One; 2011; 6(9):e24870. PubMed ID: 21949774
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A cost-utility and budget impact analysis of allogeneic hematopoietic stem cell transplantation for severe thalassemic patients in Thailand.
    Leelahavarong P; Chaikledkaew U; Hongeng S; Kasemsup V; Lubell Y; Teerawattananon Y
    BMC Health Serv Res; 2010 Jul; 10():209. PubMed ID: 20633303
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cost-Utility and Cost-Effectiveness Analysis of Spinal Cord Stimulation for Chronic Refractory Pain in the Context of Developing Country.
    Zinboonyahgoon N; Saengsomsuan N; Chaikittiporn N; Wangnamthip S; Kositamongkol C; Phisalprapa P
    Pain Physician; 2023 Jan; 26(1):69-79. PubMed ID: 36791296
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cost-effectiveness of Pulmonary Rehabilitation Among US Adults With Chronic Obstructive Pulmonary Disease.
    Mosher CL; Nanna MG; Jawitz OK; Raman V; Farrow NE; Aleem S; Casaburi R; MacIntyre NR; Palmer SM; Myers ER
    JAMA Netw Open; 2022 Jun; 5(6):e2218189. PubMed ID: 35731514
    [TBL] [Abstract][Full Text] [Related]  

  • 6. An updated cost-effectiveness analysis of pneumococcal conjugate vaccine among children in Thailand.
    Dilokthornsakul P; Kengkla K; Saokaew S; Permsuwan U; Techasaensiri C; Chotpitayasunondh T; Chaiyakunapruk N
    Vaccine; 2019 Jul; 37(32):4551-4560. PubMed ID: 31280944
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cost-utility analysis of an alcohol policy in Thailand: a case study of a random breath testing intervention.
    Vichitkunakorn P; Khampang R; Leelahavarong P; Nontarak J; Assanangkornchai S
    BMC Health Serv Res; 2024 Jun; 24(1):739. PubMed ID: 38886718
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cost-effectiveness and budget impact analyses of colorectal cancer screenings in a low- and middle-income country: example from Thailand.
    Phisalprapa P; Supakankunti S; Chaiyakunapruk N
    J Med Econ; 2019 Dec; 22(12):1351-1361. PubMed ID: 31560247
    [No Abstract]   [Full Text] [Related]  

  • 9. Cost effectiveness of rituximab and mycophenolate mofetil for neuromyelitis optica spectrum disorder in Thailand: Economic evaluation and budget impact analysis.
    Aungsumart S; Apiwattanakul M
    PLoS One; 2020; 15(2):e0229028. PubMed ID: 32050011
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cost-Utility of Video-Electroencephalography Monitoring Followed by Surgery in Adults with Drug-Resistant Focal Epilepsy in Thailand.
    Kitwitee P; Unnwongse K; Srikijvilaikul T; Yadee T; Limwattananon C
    World Neurosurg; 2017 Feb; 98():750-760.e3. PubMed ID: 27913266
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A lifetime Markov model for the economic evaluation of chronic obstructive pulmonary disease.
    Menn P; Leidl R; Holle R
    Pharmacoeconomics; 2012 Sep; 30(9):825-40. PubMed ID: 22799876
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Economic evaluation and budget impact analysis of the surveillance program for hepatocellular carcinoma in Thai chronic hepatitis B patients.
    Sangmala P; Chaikledkaew U; Tanwandee T; Pongchareonsuk P
    Asian Pac J Cancer Prev; 2014; 15(20):8993-9004. PubMed ID: 25374242
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of the cost-effectiveness of a high- and a low-intensity smoking cessation intervention in Sweden: a randomized trial.
    Nohlert E; Helgason AR; Tillgren P; Tegelberg A; Johansson P
    Nicotine Tob Res; 2013 Sep; 15(9):1519-27. PubMed ID: 23404735
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cost-effectiveness analysis of the SMART quit clinic program in smokers with cardiovascular disease in Thailand.
    Grant A; Tan CJ; Wattanasirichaigoon S; Rungruanghiranya S; Thongphiew A; Thavorn K; Chaiyakunapruk N
    Tob Induc Dis; 2023; 21():47. PubMed ID: 37035838
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Development of an economic model to assess the cost effectiveness of treatment interventions for chronic obstructive pulmonary disease.
    Spencer M; Briggs AH; Grossman RF; Rance L
    Pharmacoeconomics; 2005; 23(6):619-37. PubMed ID: 15960557
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A cost-effectiveness model of smoking cessation based on a randomised controlled trial of varenicline versus placebo in patients with chronic obstructive pulmonary disease.
    Lock K; Wilson K; Murphy D; Riesco JA
    Expert Opin Pharmacother; 2011 Dec; 12(17):2613-26. PubMed ID: 22017336
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Encouraging smokers to quit: the cost effectiveness of reimbursing the costs of smoking cessation treatment.
    Kaper J; Wagena EJ; van Schayck CP; Severens JL
    Pharmacoeconomics; 2006; 24(5):453-64. PubMed ID: 16706571
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cost-effectiveness of pharmacist-participated warfarin therapy management in Thailand.
    Saokaew S; Permsuwan U; Chaiyakunapruk N; Nathisuwan S; Sukonthasarn A; Jeanpeerapong N
    Thromb Res; 2013 Oct; 132(4):437-43. PubMed ID: 24041634
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cost-effectiveness and budget impact analysis of infliximab and its biosimilar in patients with refractory moderate-to-severe Crohn's disease using real world evidence in Thailand.
    Phisalprapa P; Kositamongkol C; Limsrivilai J; Aniwan S; Charatcharoenwitthaya P; Pisespongsa P; Kitiyakara T; Treepongkaruna S; Chaiyakunapruk N
    J Med Econ; 2020 Nov; 23(11):1302-1310. PubMed ID: 32729347
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cost-utility analysis of dasatinib and nilotinib in patients with chronic myeloid leukemia refractory to first-line treatment with imatinib in Thailand.
    Kulpeng W; Sompitak S; Jootar S; Chansung K; Teerawattananon Y
    Clin Ther; 2014 Apr; 36(4):534-43. PubMed ID: 24635968
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.